Table Of Content

VOLUME 41 1992 SUBJECT INDEX Acamprosate, 669 Barbital, 795 Clonazepam, 115 Acetaminophen, 189 Barbiturates, 355 Clonidine, 153, 519 Acetylcholine (ACh}, 23, 529, 637, 841 Basal ganglia, 547 Clozapine, 29 ACh level, 99 Behavior, 219, 321, 461, 719 Cobalt epilepsy, 813 Acquisition, 211 Behavioral CRs, 239 Cocaine binding, 227 Active avoidance, 445, 837 Behavioral effects, 377 Cocaine extinction responding, 415 Activity, 581, 587 Behavioral satiety sequence, 801 Cocaine methiodide, 851 Acute, 409 Behavioral sensitization, 841 Cocaine, 219, 227, 283, 365, 377, 415, 497, Acute exercise, 773 Behavioral tolerance, 121, 127, 133 519, 643, 659, 837, 841, 851 Added point loss, 139 Benactyzine, 377 Cocaine-maintained responding, 415 Addiction, 219 Benzodiazepine inverse agonist, 455 Codeine, 349 Adrenalectomy, 599 Benzodiazepine receptor ligands, 859 Cognition, 159 Adverse side effects, 567 Benzodiazepines, 355, 405, 461, 475, 529, Cold exposure, 795 Aging, 611 719 Conditioned avoidance response, 29 Agonist, 219 B, adrenoreceptors, 483 Conditioned drug effects, 239 Alarm cries, 551 Bicuculline, 727 Conditioned flavor aversions, 239 Alarm substance, 599 Blood-brain barrier, 255 Conditioned food aversions, 239 Albuterol, 483 Blood glucose, 295 Conditioned place preference, 817, 825 Alcohol, 49, 105, 127, 133, 355, 587, 795 Blood pressure, 567 Conditioned taste aversion, 43, 239, 245, Alcohol intake, 105 BMY-14802, 29, 215 455, 559 Alcohol-related birth defects, 587 Bone, 289 Conditioned withdrawal, 543 Alcohol sensitivity, 795 Brain, 539 Conditioning, 13 N-Allylnormetazocine, 215 Brain *H-2-deoxyglucose uptake, 295 Conflict, 399 a,-Adrenergic receptors, 267 Brain glucose, 295 Conflict behavior, 651 a>-Receptor localization, 267 Brain lesions, 727 Conspecific odors, 581 a,-Receptor subtypes, 267 Brain self-stimulation, 391 Consummatory acts, 251 Q>,, 267 Brain-stimulation reward, 755 Contingent tolerance, 121, 127, 133 QBs 267 Buspirone, 573 Continuous reinforcement, 309 Alphaxalone, 399 Convulsions, 109, 115, 121, 127, 133, 159, Alprazolam, 425 Caffeine, 659, 783 599 Amnesia, 715 Calcium channel blocking agents, 567 Copulation, 133 Amnestic agents, 761 Calcium uptake, 695 Cortex, 317, 675 Amphetamine, 29, 203, 259, 309, 837 Cannabinoids, 469 Corticosterone, 317, 643, 795 d-Amphetamine, 283, 391, 859 Carbamazepine, 109, 115, 121, 813 Corticotropin releasing factor, 399 Amygdala, 109, 115, 121, 127 Carbon monoxide, 749 Cotinine, 701 Analgesia, 53, 65, 153, 449, 665 Catalepsy, 301, 547 CQ 32-084, 683 Androgen-dependent behavior, 195 Catecholamines, 195, 329, 733, 739 Cross tolerance, 115, 127, 355 Angiotensin converting enzyme inhibitor, Cathinone, 37 Cue learning, 529 105 Central neurotransmission, 445 Cumulative dosing, 83, 365 Angiotensin II, 105 Central receptors, 461 Curiosity, 625 Angiotensin II-induced drinking, 183 Cerebellum, 761 CY 208-243, 511 Antagonism, 245, 529 CGS 10746B, 37, 807 Antagonist, 219 Chemical and electric seizures, 99 D, dopamine receptors, 235 Anticonvulsant, 109, 115, 121, 127, 789 Chick, 761 D, receptors, 321, 343 Antihypertensive agents, 567 Chickens, 349 D, agonist, 65 Antinociception, 53, 65, 371, 429 Chlordiazepoxide, 475, 529, 643 D, autoreceptors, 683 Antipredator defense, 551 Chlorpheniramine, 783 D, receptors, 259, 343, 841 Antistereotypic activity, 665 1-(m-Chlorophenyl)biguanide, 361 d-Amphetamine, 283, 391, 859 Antitussive mixture, 783 m-Chlorophenylpiperazine, 621 DADL ([D-Ala’, D-Leu*]enkephalin), 171 Anxiety, 551, 643, 683, 719 Chlorpromazine, 13 Defensive withdrawal, 643 Anxiolytic, 13, 405, 475, 573 Choice, 817 Delayed spontaneous alternation response, Anxiolytic effect, 425 Choice measures, 825 573 Apomorphine, 171, 177, 511 Cholecystokinin, 83 Delta-amino-n-valeric acid, 651 Arginine vasopressin, 409 Cholinergic, 23, 547, 625 2-Deoxy-D-glucose, 371 Aromatization, 733 Cholinergic function, 433 Dependence, 49 Atipamezole, 611 Cholinergic systems and memory, 715 Depression, 23 Atropine, 377 Cholinesterase in RBC and tissues, 773 [Des-Gly’,d(CH,),',O-Et-Tyr’, Val*,Arg’]- Attention, 195 Cholinesterase inhibitor, 251 vasopressin, 409 Autoreceptor, 841 Chronic, 409 Detection threshold, 391 Avoidance behavior, 145 Chronic ethanol, 275 Development, 69, 469 Avoidance schedule, 139 Chronic intoxication, 49 Dextromethorphan, 215 Azaprophen, 377 Cigarette smoke, 655 Diabetes, 483 Cigarette smoking, 749 Diazepam, 1, 13, 109, 121, 159, 461, 573, Baboons, 567 cis-Flupenthixol, 489 695, 859 Baclofen, 651, 695 Classical conditioning, 239 Diazepam withdrawal, 695 863 864 SUBJECT INDEX Differential conditioning, 333 Fixed-interval schedules, 377 Imipramine, 599 Differentiation, 69 Fixed-ratio schedule, 83 Immobility, 425, 507 Dihydrocodeine, 783 Flinders Sensitive Line, 23 Inclined plane, 13 Dipsogenic agent, 183 Fluid exchange, 183 Individual differences, 203 Discriminative stimulus effects, 377 Flumazenil, 529 Inferior colliculus, 727 Discriminative stimulus properties, 391 cis-Flupenthixol, 489 Inflammation, 53 Ditolyguanidine, 215 Follicle stimulating hormone, 255 Ingestive behavior, 483 DN-2327, 573 Food intake, 7, 385 Intake, 689 DOCA-salt hypertension, 567 Food-maintained responding, 415 Interactions, 13 DOI, 519 Foot-shock, 317 Intermediate-term memory, 761 Domestic fowl, 349 Four plates test, 405 Intracerebral microinjection, 727 Domoic acid, 211 FR/DRL schedule, 251 Intracerebroventricular, 409 DOPAC, 469 Frontal cortex, 637 Intraventricular, 329, 733 Dopamine, 37, 57, 75, 177, 231, 343, 469, Investigatory behavior, 625 489, 501, 511, 607, 643, 675, 683, 807, GABA, 1, 49, 405, 501, 603, 651 Ischemia, 231 841 GABA levels, 99, 669 Isradipine, 37, 497, 807 Dopamine autoreceptors, 227 GABA-T inhibitors, 603 Dopamine D, antagonist, 507 GABA, receptors, 767 Ketanserin, 53 Dopamine metabolism, 301 Gender differences, 153 Ketocyclazocine, 7 Dopamine receptors, 343 Generalization, 43 Kindling, 109, 115, 121, 127 DPLPE ({D-Pen’, L-Pen*]enkephalin), 171 Genetic model, 795 Drinking, 847 Gerbils, 231, 539 L-a-Glycerylphosphorylcholine, 445 Drug dependence, 219 Glucose, 65 Latency, 817, 825 Drug discrimination, 43, 165, 245, 321, Glucose + saccharin-maintained Lead, 289 361, 783, 789 responding, 415 Learning, 211, 587, 625 Drug discrimination learning, 245 L-a-Glycerylphosphorylcholine, 445 Learning and memory, 445, 573 Drug interaction, 83, 405, 659 Glycine, 263 Lever release, 29 Drug kinetics, 489 Gonadectomy, 153 LHRH agonist, 665 Drug reinforcement, 559, 825 Grooming, 385, 683 LHRH antagonist, 665 Drug tolerance, 133 Growth hormone, 795 Lidocaine, 851 DSP-4, 195 Gulls, 289 Limited access procedure, 385 Lisuride, 683 ECoG, 813 H, receptor, 371 Lithium, 239 Edema, 53 (?H]-5-HT release, 695 Liver, 289 EEDQ, 321 3H-GABA uptake, 669 Locomotion, 91, 227, 301, 607 Electrical resistance, 855 Haloperidol, 13, 29, 177, 215, 301, 547 Locomotor activity, 171, 203, 251, 365, Electroconvulsive shock, 663 Haloperidol decanoate, 13 377, 391, 655 Elevated plus-maze, 643 Hamsters, 543 Long-term memory, 761 Elevated plus-maze test for anxiety, 91 Hemispheric asymmetry, 761 Lorazepam, 659, 795 Eltoprazine, 801 n-Hexane, 79 LPO, 761 Eltoprazine hydrochloride (DU 28853), 581 Hippocampus, 211 LS and SS mice, 275 Emesis, 215 Histamine, 371 Luteinizing hormone, 255, 795 Endorphins, 559 Histamine-receptor, 317 Luteinizing hormone-releasing hormone, Endurance-trained exercise, 773 Homotaurine, 49 255, 665 Enhancement of memory, 295 Hot-plate, 449 LY-171555, 177 Enrichment, 689 5-HT, 53, 91 Entorhinal cortex, 767 5-HT antagonists, 53 1-(m-Chloropheny])biguanide, 361 Estrogen, 255 5-HT receptors, 53, 429, 621 m-Chlorophenylpiperazine, 621 Estrous, 153, 719 5-HT uptake inhibitors, 801 Magnesium chloride, 415 Ethanol, 127, 133, 189, 263, 409, 455, 587, 5-HT, receptors, 801 Magnesium-deficient diet, 415 663, 669, 689 5-HT,,, 5-HT,s, and 5-HT,- receptors, 519 Male sexual behavior, 511, 739 Ethanol intake, 385, 847 5-HT, antagonist, 241 Masculinization, 329 Ethyl acetate, 79 5-HT;, 361 Matching-to-sample, 283 Experimental hypocholinergic model, 5-HT; antagonists, 659 mCPBG, 519 433 5-HT; receptors, 807, 847 MDA, 333 Exploration, 625 Human, 139 MDL 72222, 37 Exploratory behavior, 91 HVA, 547 Mecamylamine, 755 Extinction, 847 HVS, PA, and WM performance, 611 Median raphe nucleus, 501 Extrahypothalamic, 329, 733 Hydrochlorothiazide, 567 Melatonin, 405 6-Hydroxydopamine, 343, 621 Memory, 1, 625, 761, 851 False precursor (NADe), 433 Hyperactivity, 501, 603 Memory consolidation, 767 False transmitter, 433 Hyperalgesia, 349 Memory modulation, 837 Fasciculin, 547 Hyperglycemia, 65 Memory retrieval, 145 Fear, 551 Hyperhydration, 183 Methamphetamine, 783 Feather, 289 Hyperphagia, 371 Methylephedrine, 783 Feed behavior, 683 Hypoalgesia, 349 2-Methylserotonin, 361 Femoxetine, 801 Methysergide, 53 Fentanyl, 615 Ibotenic acid, 607 Metoclopramide, 177 Fetal Alcohol Syndrome, 587 ICS 205-903, 37 Mice, 171, 211, 301, 365, 429, 851, 855 FI60, 475 ICS 205-930, 361, 519 Mifepristone, 69 FI behavior, 659 Idazoxan, 267, 707 Milacimide, 263 Filter perforation, 749 IMHV, 761 Minaprine, 715 SUBJECT INDEX Modified forced-swim test, 425 Para-aminoclonidine, 267 Rhesus monkeys, 159, 235, 511 Monoamine levels, 655 Para-ethoxyamphetamine, 165 Ritanserin, 241 Monoamines, 231 Para-methoxyamphetamine, 165 Ro 15-1788, 859 Morphine, 83, 245, 449, 497, 543, 551, 615, Paracetamol, 189 Ro 15-4513, 455 727, 825 Paroxetine, 801 Ro 16-6028, 859 Morris water maze, 211, 529 Partial reinforcement, 309 (R/S)-4-VinyIGABA, 603 Motor behavior, 75, 567, 707 Passive avoidance, 445, 573 RU 486, 69 Mouse striatum, 227 Passive avoidance tests, 715 Moving belt, 409 Pattern recognition, 707 (S)-4-AllenyIGABA, 603 Multitrial, 715 Paw pad, 855 SCH 23390, 177, 321, 507 Muscimol, 49, 501 Penile erection, 511 SCH 39166, 235 Mussel toxin, 211 Pentobarbital, 127, 283 Scopolamine, 529, 625, 715, 855 Myorelaxant, 13 Periaqueductal gray, 727 Seizure, 109, 115, 121, 127, 263, 365, 663 Peripheral type receptors, 461 Self-administration, 165, 219, 259, 415, N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrroli- Phencyclidine, 83, 283, 603 615, 789 dinyl) acetamide (DM-9384), 231 Phenobarbital, 115 Self-administration by naive mice, 497 N-Allylnormetazocine, 215 Phlorizin, 295 Self-stimulation, 489, 755 n-Hexane, 79 Physostigmine, 529, 773 Sensitization, 203, 275, 365 Naloxone, 245, 349, 475, 543, 755 Pigeons, 83, 283 Septum, 675 Naloxone-precipitated withdrawal, 543 Pilocarpine, 153 Serial probe recognition (SPR), 159 Naltrexone, 559 Pimozide, 13, 301, 489 Serotonin, 53, 231, 241, 329, 501, 643, 675, Naturalistic environment, 701 Place conditioning, 559, 817, 825, 859 733, 789 Neonatal, 69, 329 Place learning, 529 Sertraline, 789 Neostriatum, 675 Place task, 211 Sex differences, 551 Nerve agents, 159 Play, 817 Sexual behavior, 69, 91, 133, 329, 733 Neuroexcitant amino acid, 211 Plus maze, 13, 399 Sexual behavior and orientation, 91 Neuroexcitotoxin, 211 Posttraining, 837 Sexual differentiation, 91, 733 Neuromotor development, 587 Posttraining memory processing, 767 Sexual hormones, 329 Neurotensin, 385 (+)-3-PPP, 215 Shock-induced fighting, 49 Neurotoxin, 211 Prefrontal cortex, 607 Short-term memory, 761 Neurotransmitter system preceptors, 539 Prepregnancy, 587 Sigma site, 215 Nicotine, 23, 57, 139, 219, 701, 749, 755, Primates, 511 Single cigarette, 701 807 Proactive interference, 283 SK&F 38393, 177, 321 Nicotine abstinence, 139 Progesterone, 69, 255 SK&F 83566, 507 Nictitating membrane response, 333 Progressive degenerative dementia, 433 Sleep, 241 Nimodipine, 497 Prolactin, 795 Smoking, 701 Nitrous oxide, 429 Prostaglandin inhibitors, 189 Social reinforcement, 817 NMDA receptors, 263, 767 Psychopharmacology, 239 Sodium valproate, 109, 121 Nociception, 53 Puff-by-puff analysis, 701 Solvents and convulsions, 79 Nomifensine, 391 Pulmonary alcoholization, 669 Soman, 159 Nonhuman primates, 567 Pyridostigmine, 251 SP(1-7), 75 Noradrenaline, 231 Spatial discrimination, 817 Noradrenergic system, 739 Q-ICS 205-930, 361 Spatial learning, 1, 637 Norepinephrine, 195, 675 Quinelorane, 511 Spatial navigation, 211 Novel odors, 581 Quinpirole, 65 SQ 29,852, 105 Novelty, 203 Stereotypic behavior, 343 Nucleus accumbens, 57, 177, 203, 501 Rabbit, 333 Stereotypy, 29 Nucleus basalis, 637 Radioimmunoassay, 719 Steroids, 399 Nucleus basalis magnocellularis, 445 Rapid tolerance, 355 Stimulus properties of drugs, 37, 807 Rate of decarbamylation, 773 Straw-climbing behavior, 425 Odansetron, 53 Rats, 23, 37, 49, 53, 99, 109, 115, 121, 127, Straw suspension, 425 Oestrous, 719 133, 153, 203, 241, 317, 355, 371, 377, Stress, 317, 399, 587, 599, 607, 615, 663 8-OH-DPAT, 519 409, 415, 461, 475, 507, 511, 529, 539, Striatum, 203 Olfactory preference, 581 573, 587, 607, 655, 675, 707, 783, 801, Subcutaneous, 409 One-way active avoidance, 851 807, 813, 817, 825, 837 Submissive odors, 581 Ontogeny, 621 Rattus norvegicus, 625 Substance P, 75 Open field, 733 Rauwolscine, 267 Substantia nigra, 75 Open-field behavior, 675 Rearing, 655 Successive discrimination, 475 Operant behavior, 251 Receptor autoradiography, 539 Sulpiride, 29, 301 Opiate antagonists, 43, 559 Red nucleus lesions, 99 Supersensitivity, 343, 519 Opiate withdrawal, 543 Reflex modification, 333 Supersensitization, 621 Opiates, 349, 559 Regulation, 219 Sustained release, 219 Opioid, 219, 349 Reinforcement, 165, 219, 489 Swim, 607 Opioid receptor, 65 Remoxipride, 259 Oral dyskinesia, 621 Renin-angiotensin system, 105 Tail-flick, 449 Organic solvents, 79 Renovascular hypertension, 567 Tail suspension test, 405 Organophosphate, 159 Resistance to extinction, 309 Taste conditioning, 559 Oxytocin, 7 Respiration, 349 Taste reactivity, 559 Resting, 385 Taste reactivity test, 239 P and NP rats, 105 Restraint stress, 449 Testosterone, 255 Pain, 53, 349 Restricted access, 847 TFMPP, 519 Palatability, 559 Reward, 489, 859 THA, 637 866 SUBJECT INDEX Thalamus, 675 TRH, 145 Vocal control system, 195 Thermal nociception, 349 Triiodothyronine, 145 Vocalizations, 739 Thermoregulation, 23 Trimethadione, 115 Thiazide diuretics, 567 Turning, 177 Waking, 241 Thioridazine, 13 Tyrosine hydroxylase, 469 Water, 817 Thyrotropin, 795 Water intake, 251, 385, 847 Thyroxine, 145 Ultrasonic vocalization, 551 Wet-dog shakes, 99 Tissue deposition, 289 Up-regulation, 235 Wild running, 727 Titration schedule, 283 Withdrawal, 49 Tobacco abstinence, 139 Vaginal opening, 69 Tobacco administration, 139 Valproic acid, 109, 121 X-maze, 683 Tobacco smoke exposure reduction, Vasopressin, 7, 409 749 Ventral mesencephalon, 675 Yohimbine, 267, 707 Tolerance, 109, 115, 121, 127, 275, 409 Verapamil, 567 Toluene, 79 Vigabatrin, 603 Zacopride, 847 Toxin, 547 Visual discrimination, 251 Zolantidine, 371 AUTHOR INDEX Abel, E. L., 599 Darmani, N. A., 519 Gottesmann, C., 241 Knapp, D. J., 847 Airaksinen, M. M., 701 De Miguel, R., 469 Grauffel, C., 603 Koch, J. E., 371 Alburges, M. E., 267 Dell’anna, E., 231 Grunberg, N. E., 615 Kogure, K., 539 Allen, R. P., 567 Desouza, E. B., 483 Grupp, L. A., 105 Kojima, H., 231 Alvares, K., 615 Destrade, C., 177 Guardiola-Lemaitre, B., 405 Kolasa, K., 99 Ambrogi Lorenzini, C., 715 Deutsch, S. I., 263, 663 Gui-Hua, C., 321 Kolonen, S., 701 Amit, Z., 259 Dewitte, P., 669 Guidi, G., 445 Koob, G. F., 399 Ando, K., 783 Di Scala, G., 727, 859 Gulati, K., 7 Kornetsky, C., 755 Andrews, N., 695 Dilsaver, S. C. 23 Korpi, E. R., 795 Araki, T., 539 Dodson, D. L., 625 Hall, J. L., 295 Kostrzewa, R. M., 621 Araki, Y., 655 Domanague, K. R., 455 Hall, M. E., 75 Kulkosky, P. J., 385 Arolfo, M. P., 1 Drago, F., 445 Haracz, J. L., 29 Kuzmin, A., 497 Dube, S. N., 773 Harding, C. F., 195 Bagri, A., 727 Duffy, R. A., 235 Hauger, R., 399 Lammintausta, R., 611 Baldi, E., 715 Dukat, M., 361 Heidbreder, C., 669 Larsen, T., 159 Banks, W. A., 255 Dunn, A. J., 643 Henningfield, J. E., 189 Lau, Y.-S., 57 Barclay, S. R., 195, 739 Durbin, P., 669 Hernandez, M. L., 469 Lauretz, S. D., 433 Barfield, R. J., 69 Hicks, L. H., 455 Lauria, N., 445 Barrera, C. M., 255 Emmanouilidis, E., 49 Hienz, R. D., 567 Lawley, S. I., 415 Bennett, E. L., 761 Erwin, V. G., 275 Holtzman, S. G., 449 Leduc, P. A., 625 Bennett, R. H., 139 Hooks, M. S., 203 Legrand, E., 669 Bilitzke, P. J., 599 Farabollini, F., 91 Hopper, D. L., 707 Lenégre, A., 405 Billing, A. E., 719 Fargeas, M. J., 461 Hough, L. B., 371 Lepore, M., 489 Bitar, M. S., 483 Fasold, M. B., 255 Hudda, M. M., 115 Leret, M. L., 329, 733 Blanchard, D. C., 551 Felch, L. J., 749 Hudzik, T. J., 215 Levin, E. D., 219 Blanchard, R. J., 551 Feldon, J., 309 Hughes, R. A., 349 Lewis, M. J., 455 Blengio, M., 317 Fernandez-Ruiz, J. J., 469 Hunt, M.A. E., 267 Lindqvist, E., 231 Bodnar, R. J., 153, 371 Ferrari, F., 683 Huston, J. P., 675 Liu, J.-F., 409 Bolioli, B., 547 Ferrario, P., 99 Huston-Lyons, D., 755 Liu, W.-F., 251 Booth, R. A., 433 Ferreira, M. B. C., 767 Hutto, C. W., Jr., 817, 825 Lodge, B. A., 165 Bose, R., 211 Ferretti, C., 317 Lukacs, L. G., 263 Bowes, M. P., 707 File, S. E., 695 Ishida, Y., 539 Lummis, G. H., 455 Brigham, J., 749 Fillmore, M. T., 13 Izquierdo, I., 767 Luthman, J., 231 Brioni, J. D., 1 Finger, A. V., 159 Britton, K. T., 399 Franklin, K. B. J., 489 Janak, P. H., 837, 851 MacNeil, D. A., 145 Bucherelli, C., 715 Fratta, W., 497 Jaskiw, G. E., 607 Mana, M. J., 109, 121 Bueno, L., 461 Fregly, M. J., 183 Jenden, D. J., 433 Mandel, R. J., 343 Burger, J., 289 Fry, J. P., 719 Jensen, K., 239 Mannisto, P. T., 795 Bylund, D. B., 267 Fujiwara, H., 301 Johnson, K. M., 841 Martellotta, M. C., 497 Fukuda, N., 573 Jones, B. C., 275 Martin, B. R., 519 Cade, J. R., 183 Fung, Y. K., 57 Jones, C. H., 121 Martinez, J. A., 461 Calcagnetti, D. J., 449 Jones, G. H., 203 Martinez, J. L., Jr., 837, 851 Carey, M. P., 719 Gamzu, E. R., 145 June, H. L., 455 Mastropaolo, J., 263, 663 Castell6, M. E., 547 Genovese, R. F., 377 June, P. L., 455 Mauceri, F., 445 Castresana, A., 49 George, F. R., 189 Junien, J.-L., 659 McGuirk, J., 801 Castro, C. A., 159 Gessa, G. L., 497 Justice, J. B., Jr., 203 McLeod, S., 399 Chang, A. S., 433 Geter, B., 43 McMaster, S. B., 159 Cheng, M.-F., 739 Gewiss, M., 669 Kadar, T., 665 McNamara, R. K., 529 Cherek, D. R., 139 Ghi, P., 317 Kalant, H., 355, 409 McNaughton, N., 475 Chiang, P. K., 377 Gibson, J. E. M., 689 Kameyama, T., 171 McQuade, R. D., 235 Chipkin, R. E., 235 Gifford, A. N., 841 Kaminska, G., 235 Medina, J. H., 767 Christensen, B. K., 133 Giordano, J., 53 Kantak, K. M., 415 Meehan, S. M., 807 Ciancone, M. T., 29 Giuliani, D., 683 Kastin, A. J., 255 Messier, C., 177 Coen, K. M., 165 Glavin, G. B., 211 Kato, H., 539 Meyer, M. E., 507 Colasanti, B. K., 813 Glennon, R. A., 361 Kautz, M. A., 43 Michael, R. P., 391 Consolo, S., 99 Glesson, R. A., 519 Kawashima, T., 855 Mihic, S. J., 409 Corrigall, W. A., 165 Glin, L., 241 Keis, A. F., 483 Mrabet, O., 177 Cotton, D. B., 599 Gochfeld, M., 289 Kemble, E. D., 581 Mueller, J. L., 429 Cottrell, G. A., 507 Goeders, N. E., 643 Kernan, W. J., Jr., 707 Mulven, R., 483 Cottrill, K. L., 295 Gold, P. E., 295 Khanna, J. M., 355 Muscat, R., 801 Craig, C. R., 813 Gomita, Y., 655 Kiefel, J. M., 153 Crowder, W. F., 817, 825 Gong, L., 621 Kim, C. K., 109, 115, 121, 127 Nader, M. A., 789 Gonzalez, I., 91 Kimball, K. A., 283 Nardo, L., 445 Da Silva, R. C., 767 Gonzalez, M. I., 329, 733 Kirkpatrick-Steger, K., 333 Neill, D. B., 203 Dajas, F., 547 Gorman, A. L., 643 Klein, S. A., 189 Nespor, S. M., 615 Daoust, M., 669 Gormezano, I., 333 Kleinrok, Z., 99 Nishimura, H., 425 868 AUTHOR INDEX Norris, D. O., 263 Ray, A., 7 Sharma, K. K., 7 Vander Linden, S., 333 Novitzki, M. R., 263, 663 Rebec, G. V., 29 Shephard, R. A., 651 Vanover, K. E., 789 Reilly, R. T., 295 Shepherd, J. K., 551 Verderese, A. G., 145 O’Connor, D. A., 263 Reilly, S. M., 289 Shiotani, T., 231 Vincent, G. P., 145 O’Connor, T., 415 Reith, M. E. A., 227 Shiotsuki, N., 79 Oberling, P., 859 Renner, M. J., 625 Shuto, K., 539 Oishi, R., 655 Rennie, M., 559 Silhol, S., 241 Wada, T., 573 Olson, L., 231 Rice, K. M., 433 Silva-Filho, A. R., 79 Wainwright, M., 543 Orikasa, S., 855 Riedel, C. A., 851 Sirvid, J., 611, 637 Wamsley, J. K., 267 Ostrem, J. L., 581 Riekkinen, M., 611, 637 Skelton, R. W., 529 Wasserman, S. J., 415 Overstreet, D. H., 23 Riekkinen, P., 611 Smith, B. R., 259 Waterman, S. A., 195 Owusu,S. E., 483 Riekkinen, P., Jr., 611, 637 Smurthwaite, S. T., 43 Wedlock, P., 651 Riley, A. L., 43, 245 Solana, R. P., 159 Weinberger, D. R., 607 Parker, L. A., 239, 559 Roane, D. S., 65 Somani, S. M., 773 Weinberger, S. B., 851 Paul, D., 65 Robertson, J. M., 165 Soulairac, A., 49 Weiner, I., 309 Payan, C., 49 Roch, M., 433 Standish, N. M., 211 Weiner, J., 355 Peck, J. A., 23 Rocha, B., 859 Stevenson, G. W., 245 Weinstein, M. A., 69 Pelloni, F., 683 Rockman, G. E., 689 Stewart, J. M., 75 Weiss, S. M., 551 Perry, B. D., 321 Rodgers, R. J., 551 Stitzer, M. L., 749 Wenger, G. R., 283 Peters, R. H., 707 Rodriguez de Fonseca, F., Stone, W. S., 295 Wettstein, J. G., 659 Petrie, B. F., 211 469 Stwertka, S. A., 145 White, I. M., 29 Pfaus, J. G., 133 Roese, N. R., 127 Suemaru, K., 655 Wilcox, R. E., 343 Pickworth, W. B., 189 Rose, J. E., 219 Sufka, K. J., 53, 349 Willner, P., 801 Pinel, J. P. J., 109, 115, 121, Rosenzweig, M. R., 761 Wilson, C. A., 91 127, 133 Rouhani, S., 49 Tachizawa, H., 231 Wilson, K. M., 183 Pinsky, C., 211 Rowland, N. E., 183 Tanaka, M., 425 Wilson, N. E., 651 Pires, M. L. N., 79 Ruggles, J. L., 13 Tassoni, G., 715 Winsauer, P. J., 83 Pleim, E. T., 69 Russell, R. W., 433 Taukulis, H. K., 13 Wirtshafter, D., 501 Poenaru, S., 49 Telegdy, G., 665 Witkin, J. M., 377 Poherecky, L. A., 847 Saeki, K., 655 Terry, P., 365 Witkin, K. M., 377 Pomerantz, S. M., 511 Saito, M., 855 Thompson, D. M. 83 Wong, D. J., 115 Porsolt, R. D., 405 Sandner, G., 727, 859 Torres, F. K., 587 Woolverton, W. L., 321, 789 Portaleone, P., 317 Sandoval, S. L., 385 Toyoshi, T., 171 Wu, P. H., 409 Pournaghash, S., 245 Schaefer, G. J., 391 Tran, G., 49, 669 Puustinen, P., 701 Schally, A. V., 665 Trifunovic, R., 501 Yanagita, T., 783 Schechter, M. D., 37, 807 Tripp, G., 475 Yang, X.-M., 643 Quock, R. M., 429 Schnur, P., 543 Tuominen, K., 795 Young, R., 361 Schomburg, F. M., 53 Tuomisto, J., 701 Yung, A., 115 Radcliffe, R. A., 275 Schwarting, R. K. W., 675 Turkkan, J. S., 567 Ramos, J. A., 469 Seiler, N., 603 Rampello, L., 445 Selmeci, G., 227 Ukai, M., 171 Zecca, L., 99 Ramus, S. J., 761 Serrano, P. A., 761 Zharkovsky, A., 695 Randall, P. K. 343 Shah, G., 355 Valerio, C., 445 Zimmerberg, B., 587 Rawleigh, J. M., 581 Shaham, Y., 615 Van Hartesveldt, C., 507 Zvartau, E., 497